Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD

References

• Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173–7.
   PubMed Web of Science ®Google Scholar
• Fiehn C, Belke-Voss E, Krause D, Wassenberg S, Rau R. Improved radiological outcome of rheumatoid arthritis: the importance of early treatment with methotrexate in the era of biological drugs. Clin Rheumatol. 2013;32(12):1735–42.
   PubMed Web of Science ®Google Scholar
• Sewerin P, Müller-Lutz A, Abrar DB, Odendahl S, Eichner M, Schneider M, et al. Prevention of the progressive biochemical cartilage destruction under methotrexate therapy in early rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(2):179–85.
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328(18):1317–21.
   PubMed Web of Science ®Google Scholar
• Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, et al. Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2009;26(1):1–9.
   PubMed Web of Science ®Google Scholar
• Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatol (Oxford). 2017;56(6):940–6.
   PubMed Web of Science ®Google Scholar
• Inui Y, Matsuoka H, Yakushijin K, Okamura A, Shimada T, Yano S, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56(11):3045–51.
   PubMed Web of Science ®Google Scholar
• Takanashi S, Aisa Y, Ito C, Arakaki H, Osada Y, Amano Y, et al. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression. Rheumatol Int. 2017;37(10):1629–33.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Saito S, Okuyama A, Suzuki K, Higashi M, Momose S, et al. Clinicopathologic investing of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018;59(5):1143–52.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Sada KE, Yan M, Zeggar S, Hiramatsu S, Miyawaki Y, et al. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol. 2017;27(5):773–7.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.
   PubMed Web of Science ®Google Scholar
• Kameda T, Dobashi H, Miyatake N, Inoo M, Onishi I, Kurata N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res. 2014;66(9):1302–9.
   PubMed Web of Science ®Google Scholar
• Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28(1):1–8.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Tamaru J, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. Jceh. 2019;59(2):72–92.
   Google Scholar
• Tokuhira M, Saito S, Suzuki K, Higashi M, Momose S, Shimizu T, et al. Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders. Leuk Lymphoma 2019;60(10):2508–15.
   PubMed Web of Science ®Google Scholar
• Tsukui D, Kanda H, Shinozaki-Ushiku A, Tateishi S, Takeshima Y, Nagafuchi Y, et al. Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome. Mod Rheumatol. 2018;28(4):621–5.
   PubMed Web of Science ®Google Scholar
• Takanashi S, Nakazato T, Aisa Y, Ito C, Arakaki H, Osada Y, et al. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders. Ann Hematol. 2018;97(9):1611–8.
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol. 1994;25(7):638–43.
   PubMed Web of Science ®Google Scholar
• Miyashita EM, Yang B, Lam KMC, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995;80(4):593–601.
   PubMed Web of Science ®Google Scholar
• Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Yamaoka K, Shimizu T. Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment. Front Immunol 2018;9:621.
   PubMed Web of Science ®Google Scholar
• Feng W, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-mansky R, et al. Reactivation of latent Epstein – Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22):1691–702.
   PubMedGoogle Scholar
• Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Sato H, Nakatsue T, Wada Y, Murakami S, Nakano M, et al. Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report. BMC Res Notes. 2014;7(1):229.
   PubMedGoogle Scholar
• Tokuhira M, Watanabe R, Nemoto T, Sagawa M, Tomikawa T, Tamaru JI, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012;53(4):616–23.
   PubMed Web of Science ®Google Scholar
• Pfizer-Japan-Inc. Rheumatrex proper use information. In. 21., vol. 21. Tokyo; 2014. p. 19–22.
   Google Scholar
• Balandraud N, Texier G, Massy E, Muis-Pistor O, Martin M, Auger I, et al. Long term treatment with Abatacept or Tocilizumab does not increase Epstein-Barr Virus load in patients with Rheumatoid arthritis – a three years retrospective study. PLoS One. 2017;12(2):e0171623.
   PubMed Web of Science ®Google Scholar